Zeitschrift für Immunbiologie

Enhancing Immune Checkpoint Inhibitors with CRISPR: A Revolutionary Approach to Cancer Immunotherapy

Abstract

Stefanie Qian

Cancer immunotherapy has revolutionized the treatment landscape, with Immune Checkpoint Inhibitors (ICIs) playing a pivotal role in harnessing the body's immune system to combat cancer. However, not all patients respond equally to ICIs, necessitating the exploration of innovative strategies to enhance their effectiveness. This article explores the emerging field of using CRISPR-Cas9 gene editing technology to augment the therapeutic potential of ICIs. By targeting specific genes and pathways involved in immune response regulation, CRISPR holds the promise of improving the outcomes of cancer patients and advancing the future of precision medicine. Some cancer cells develop resistance to ICIs by upregulating alternative immune checkpoints. CRISPR can be employed to disrupt the expression of these checkpoints, making cancer cells more susceptible to ICI therapy. The tumor microenvironment plays a pivotal role in cancer progression and response to immunotherapy. CRISPR can be used to modify immune cells and stromal cells within the tumor microenvironment, promoting an immune-favorable environment and enhancing the response to ICIs.